Table 1.

Summary of clinical trials using glucagon-like peptide-1 (GLP-1) analogues for the treatment of type 2 diabetes.

Baseline treatment	Product	Comparator	Duration (weeks)	n	Δ HbA1c	Δ Weight (kg)	Reference
GLP-1 only	Liraglutide	Placebo	14	42	−1.4	N/A	Vilsbøll et al. [2007]
GLP-1 only	Liraglutide	Glimepiride	52	251	−0.84	−2.00	Garber et al. [2009]
Metformin	Exenatide	Placebo	30	113	−0.80	−2.80	DeFronzo et al. [2005]
Metformin	Liraglutide	Glimepiride or placebo	26	240	−1.00	−2.60	Nauck et al. [2009a]
Metformin	Liraglutide	Sitagliptin	26	225	−1.24	−2.86	Pratley et al. [2010]
Metformin	Exenatide	None	82	92	−1.30	−5.30*	Ratner et al. [2006]
SU	Exenatide	Placebo	30	129	−0.86	−1.60	Buse et al. [2004]
SU	Liraglutide	TZD or placebo	26	228	−1.10	0.30	Marre et al. [2009]
TZD±MF	Exenatide	Placebo	16	121	−0.89	−1.75	Zinman et al. [2007]
MF + TZD	Liraglutide	Placebo	26	178	−1.50	−1.00	Zinman et al. [2009]
MF + SU	Exenatide	Placebo	30	241	−0.80	−1.60	Kendall et al. [2005]
MF + SU	Liraglutide #	Glargine	26	230	−1.09	−1.80	Russell-Jones et al. [2009]
MF + SU	Exenatide	Glargine	26	275	−1.11	−2.30	Heine et al. [2005]
MF + SU	Exenatide	Novomix	52	253	−1.04	−2.50	Nauck et al. [2007]

All doses of exenatide are 10 μg twice daily and liraglutide 1.2 mg daily unless otherwise stated. Weight loss quoted is against the baseline weight in the GLP-1 agonist treatment arm. n = number of subjects in the treatment arm of the study.

^*Open-label extension study.

^#Liraglutide dose 1.8 mg daily.

MF, metformin; SU, sulphonylurea; TZD, thiazolidinedione.